Effects of supervised aerobic exercise on cardiorespiratory fitness and patient-reported health outcomes in colorectal cancer patients undergoing adjuvant chemotherapy—a pilot study

Eva M. Zopf1,2 · Holger Schulz3 · Jonas Poeschko4,5 · Kerstin Aschenbroich1,5 · Thomas Wilhelm6 · Ernst Eypasch7 · Elmar Kleimann8 · Kai Severin9 · Jutta Benz10 · Enwu Liu2 · Wilhelm Bloch1 · Freerk T. Baumann1,5

Abstract
Purpose Colorectal cancer and its treatment are associated with debilitating side effects. Exercise may improve the physical and psychological wellbeing of cancer patients; however, evidence in colorectal cancer patients undergoing adjuvant chemotherapy is limited. This pilot study aimed to explore the effects of supervised aerobic exercise on cardiorespiratory fitness and patient-reported health outcomes in colorectal cancer patients undergoing adjuvant chemotherapy.

Methods Patients who had undergone curative resection for colorectal cancer (stages II–III) and were scheduled to receive adjuvant chemotherapy were enrolled into this non-randomized controlled trial. Patients in the intervention group (IG) took part in a 6-month supervised aerobic exercise program, while the control group (CG) received usual care. Cardiorespiratory fitness (measured by peak oxygen consumption) was assessed at baseline and 6 months. Fatigue, quality of life, and physical activity levels were additionally assessed at 3 months.

Results In total, 59 patients (33 in IG vs. 26 in CG) were enrolled into this study. Eighteen patients (9 in IG vs. 9 in CG) dropped out of the study prior to the 6-month follow-up. Significant improvements in cardiorespiratory fitness (p = .002) and selected patient-reported health outcomes, such as reduced motivation (p = .015) and mental fatigue (p = .018), were observed in the IG when compared to the CG.

Conclusion To our knowledge, this is the first study to investigate the effects of a supervised aerobic exercise program in colorectal cancer patients undergoing adjuvant chemotherapy. The significant and clinically meaningful improvements in CRF warrant further randomized controlled trials to confirm these findings.

Trials registration German Clinical Trials Register Identifier: DRKS00005793, 11/03/2014, retrospectively registered.

Keywords Physical activity · Physical fitness · Fatigue · Quality of life · Colorectal neoplasms
Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide and while survival rates continue to improve, it remains the second most common cause of cancer death [1]. Treatment for CRC is dependent on a variety of factors; however, one of the most common treatment regimens in patients treated with curative intent is surgical resection in combination with adjuvant chemotherapy [2]. Although this treatment approach has proven to extend survival [3], it is often accompanied by debilitating adverse effects including but not limited to pain, fatigue, nausea, diarrhea, mucositis, and peripheral neuropathy [4–6]. Furthermore, physical activity levels, physical fitness, and functional capacity have shown to deteriorate during and following CRC treatment, significantly impacting patients’ quality of life (QoL) [7–9]. Poor cardiorespiratory fitness (CRF) has also been associated with increased morbidity [10, 11], and cancer-specific mortality after CRC diagnosis and treatment [12, 13].

The role of physical activity and exercise in the management of cancer and its treatment-related side effects is receiving increasing attention. The recently updated American College of Sports Medicine Exercise Guidelines for Cancer Survivors suggest that exercise has a beneficial effect on a number of cancer-related health outcomes, including fatigue, physical functioning, and health-related QoL [14]. However, the majority of the evidence provided comes from studies involving breast, prostate, or hematological cancer patients. Prospective studies involving CRC patients remain scarce, especially those conducted during CRC treatment [15–17]. In fact, to our knowledge, only five controlled trials have explored the effects of aerobic and resistance exercise specifically in CRC patients undergoing adjuvant chemotherapy. All five studies involved relatively small sample sizes (12–45 patients) and a combined aerobic and resistance exercise program [18–22]. Improvements in fatigue, physical function, role function, pain, nausea, neurotoxicity symptoms, and physical activity levels have been observed [18, 20, 22]. Preliminary evidence also suggests beneficial effects of exercise on chemotherapy completion rates in CRC patients [22].

While aerobic exercise has shown to improve physical fitness, muscle strength, and QoL in breast cancer patients receiving chemotherapy [23, 24], the effects of aerobic exercise in CRC patients undergoing chemotherapy are largely unknown. In a randomized controlled trial involving CRC survivors, some of which were receiving chemotherapy, a home-based aerobic exercise program did not significantly improve health-related QoL, fatigue, or cardiovascular fitness compared to usual care [25]. In a secondary analysis, however, an increase in cardiovascular fitness was associated with improvements in QoL [25]. The effects of a supervised aerobic exercise program in CRC patients undergoing chemotherapy have not yet been explored, although supervised exercise programs are suggested to be more effective than unsupervised/home-based interventions [14, 17].

The CoAktiv study is a non-randomized controlled pilot study, which examined the effects of supervised aerobic exercise training on CRF and patient-reported health outcomes in CRC patients undergoing curative chemotherapy.

Patients and methods

Participants

Participants were recruited through three private practices and four hospitals in Cologne, Germany. Eligibility criteria included patients who had undergone curative resection for CRC (stages II–III) and were scheduled to receive adjuvant chemotherapy for at least 6 months. Patients had to be at least 18 years of age and provide written informed consent. Patients were excluded if they presented with severe hypertension or heart disease (NYHA III–IV), ongoing thrombocytopenia (<10000/μl), congenital or acquired thrombocytopenia or coagulation disorder, respiratory failure, seizure disorder, mental disorder, WHO/ECOG performance status > 2, a physical disability that impeded the use of a cycle ergometer or any other health problem that ruled out regular PA as deemed by their treating physician. Female patients were also excluded if they were pregnant.

Design

This study was a prospective, 2-armed, non-randomized controlled trial. Potential participants were primarily identified by their treating oncologist and referred to the study coordinator for eligibility screening. Patients that were eligible and willing to participate were invited for baseline testing which included physical fitness testing and the completion of the study questionnaires. To maximize safety, all patients received a medical check-up at baseline, including a resting electrocardiography (ECG), stress ECG, and cardiac ultrasound. Following baseline testing participants were allocated to either the intervention group (IG) or the control group (CG) based on their preference. All patients provided written informed consent prior to participation. Ethical approval was obtained through the ethics committee of the German Sport University Cologne and the study was registered with the German Clinical Trials Registry (DRKS00005793). All procedures conformed to the standards set by the Declaration of Helsinki.
Exercise intervention

After baseline testing, patients in the IG took part in a 6-month aerobic exercise program while undergoing chemotherapy. Two sessions per week were supervised by an exercise physiologist and included 30 min of cycling on a stationary bicycle. Additionally, patients in the IG were encouraged to complete three 15-min home-based walking sessions per week. The aim was for patients to exercise at a “somewhat hard” to “hard” intensity, measured based on the Borg rating of perceived exertion (RPE) scale [26].

The primary endpoint of this study was CRF, measured by VO2peak, which was assessed at baseline (before the exercise intervention/prior to chemotherapy) and at 6 months (after the exercise intervention/post chemotherapy). Fatigue was assessed using the Multidimensional Fatigue Inventory (MFI-20) [28]. QoL was assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and its colon cancer–specific module (EORTC-QLQ-CR29) [29, 30]. Physical activity levels (hours per week of leisure time and sport activities) were recorded by means of the Freiburger Questionnaire of Physical Activity [31].

Assessment of primary and secondary endpoints

The primary endpoint of this study was CRF, measured by VO2peak, which was assessed at baseline (before the exercise intervention/prior to chemotherapy) and at 6 months (after the exercise intervention/post chemotherapy). In order to assess CRF, a CPET on a cycle ergometer was conducted using a modified WHO protocol. The initial work load of 30 watts was increased by 15 watts every 2 min until one of the following conditions occurred: the minute ventilation or ventilation equivalent increased excessively, the ventilation equivalent reached a value between 28 and 30, the respiratory quotient exceeded 1.0, muscular fatigue set in, the patient felt exhausted (RPE ≥ 17), or any complications or symptoms interfered with the testing procedure. During the CPET, relative peak oxygen uptake (VO2peak; in mL/kg/min) as well as the maximal achieved work rate (Wattmax; in watt) and heart rate (HRmax; in bpm) were recorded. As a clear plateau in VO2 may not be achieved before symptom limitation of exercise in clinical populations, VO2peak was defined as the highest oxygen uptake attained during the test. The proportion of patients that achieved a maximal heart rate > 85% of age-predicted maximal heart rate and/or a respiratory exchange ratio (RER) > 1.10 was assessed, to provide an indication of the proportion of patients that gave a maximal effort based on these objective physiological measures [27]. Prior to each CPET, weight and body mass index (BMI) were assessed.

The secondary endpoints included fatigue, QoL, and physical activity levels. These were assessed at baseline, 3 months, and 6 months (after the exercise intervention/post chemotherapy). Fatigue was assessed using the Multidimensional Fatigue Inventory (MFI-20) [28]. QoL was assessed using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and its colon cancer–specific module (EORTC-QLQ-CR29) [29, 30]. Physical activity levels (hours per week of leisure time and sport activities) were recorded by means of the Freiburger Questionnaire of Physical Activity [31].

Statistical analyses

As this study was designed to be a pilot study, a pragmatic approach was taken to determine the sample size. Based on the number of patients treated in the collaborating hospitals and the interest expressed by patients in a prior evaluation, the aim was to recruit 60 patients, 30 per group.

Analyses were performed using IBM SPSS Statistics for Windows, Version 25.0 and included descriptive statistics, independent t tests, Fisher’s exact test, and mixed models analysis for repeated measures. Student’s t test and Fisher’s exact test were used to compare groups at baseline. Between-group differences in mean changes for individual outcomes were calculated using mixed-model repeated measure analysis. The covariates included in the mixed models approach were group, visit, visit x group and the baseline value for the outcome variables. Participants were treated as random group differences in mean changes for individual outcomes were calculated using mixed-model repeated measure analysis. The covariates included in the mixed models approach were group, visit, visit x group and the baseline value for the outcome variables. Participants were treated as random group differences in mean changes for individual outcomes were calculated using mixed-model repeated measure analysis. The covariates included in the mixed models approach were group, visit, visit x group and the baseline value for the outcome variables. Participants were treated as random group differences in mean changes for individual outcomes were calculated using mixed-model repeated measure analysis. The covariates included in the mixed models approach were group, visit, visit x group and the baseline value for the outcome variables. Participants were treated as random group differences in mean changes for individual outcomes were calculated using mixed-model repeated measure analysis. The covariates included in the mixed models approach were group, visit, visit x group and the baseline value for the outcome variables. Participants were treated as random group differences in mean changes for individual outcomes were calculated using mixed-model repeated measure analysis. The covariates included in the mixed models approach were group, visit, visit x group and the baseline value for the outcome variables. Participants were treated as random group differences in mean changes for individual outcomes were calculated using mixed-model repeated measure analysis. The covariates included in the mixed models approach were group, visit, visit x group and the baseline value for the outcome variables. Participants were treated as random
Results

One-hundred and twelve patients were screened for participation from October 2010 to April 2016. Of the 72 patients (64.3%) that initially expressed interest, 59 patients (52.7%) met all the eligibility criteria and were enrolled into the study. Participants were able to choose between either the exercise intervention or usual care for the duration of their chemotherapy. Eighteen patients (30%) dropped out of the study, nine (27.3%) in the IG and nine (34.6%) in the CG. Reasons for withdrawal included time commitment \( (n = 7) \), treatment-related toxicities \( (n = 5) \), and psychological issues \( (n = 1) \). Six patients did not provide a reason (Fig. 1).

Baseline characteristics of the study participants are presented in Table 1. Thirty-three (55.9%) women and 26 men (44.1%) were included in the study, with the majority of patients being diagnosed with a stage IIIB tumor. There were no statistically significant differences between the two groups at baseline. There were also no statistically significantly differences between participants who withdrew from the study compared to those who completed the study (Online resource 1). No severe exercise-related adverse events were reported in the IG. Available training data \( (n = 23) \) shows, that on average, patients in the IG that completed the trial attended 67.9% of their exercise sessions (range 39.58–95.83). The attendance rate was 61.9% when including patients that withdrew from the study (range 20.83–95.83). The mean initial training intensity/training load for patients in the IG was set to 63.8% of V02peak and 58.6% of Wattmax following patients’ RPE rating after the first training session.

Primary outcome

The effect of the exercise intervention on CRF is summarized in Table 2 and Online resource 3. Relative V02peak and Wattmax improved in the IG compared to the CG (mean difference 4.11 ml/kg/min; 95% CI, 1.52–6.71; \( p = 0.002 \) and mean difference 16.14 W; 95% CI, 5.71–26.57; \( p = 0.003 \), respectively). Relative VO2peak and Wattmax improved by 3.57 ml/kg/min (95% CI, 1.90–5.25; \( p < 0.001 \)) and 22.20 W (95% CI, 15.55–28.85; \( p < 0.001 \)), respectively, from

Fig. 1 Flow of participants through the study
baseline to post-intervention within the IG. Cohen’s $d$ effect sizes for VO2peak and Wattmax were moderate (0.53 and 0.51, respectively) at post-intervention. Based on achieving a maximal heart rate $> 85\%$ of age-predicted maximal heart rate and/or a RER $> 1.10$, 86% and 95% of patients gave a maximal effort in their CPET at baseline and post-intervention, respectively. Weight and BMI increased significantly within both groups from baseline to post-intervention, with no significant difference between groups.

**Secondary outcomes**

The effects of the exercise intervention on patient-reported health outcomes and physical activity levels are summarized in Table 3, Online resource 2, and Online resource 3. With regard to the MFI, differences between groups in favor of the IG were observed for reduced motivation at 3 months and 6 months (mean difference $-2.07; 95\%$ CI $-3.73$–$-0.41; p = 0.015$, Cohen’s $d$ effect size 0.29 and mean difference $-1.94; 95\%$ CI $-3.79$–$-0.09; p = 0.040$, Cohen’s $d$ effect size 0.36, respectively) and mental fatigue at 3-months (mean difference $-2.23; 95\%$ CI $-4.06$–$-0.09; p = 0.018$, Cohen’s $d$ effect size 0.36). Group differences in fatigue were primarily apparent at 3 months, with general fatigue, reduced motivation, and mental fatigue increasing by 2.34 (95% CI, 0.68–4.01; $p = 0.003$), 1.80 (95% CI, 0.25–3.35; $p = 0.017$), 1.99 (95% CI, 0.28–3.70; $p = 0.017$), respectively, in the CG from baseline to 3 months.

With regard to the EORTC-QLQ C30, a between-group difference was observed in role function in favor of the IG at 3 months (mean difference 19.64; 95% CI, 3.47–35.81; $p = 0.018$; Cohen’s $d$ effect size 0.36). Nausea/vomiting increased within both groups from baseline to 3 months (IG: mean difference $-10.01; 95\%$ CI $-16.43$–$-3.60; p = 0.001$; CG: mean difference $-10.33; 95\%$ CI $-17.87$–$-2.80; p = 0.004$). In relation to the EORTC-QLQ CR29, an improvement in favor of the IG was observed for urinary

### Table 1
Baseline characteristics of patients in the intervention and control group

|                        | Intervention group ($n = 33$) | Control group ($n = 26$) | $P$ value |
|------------------------|------------------------------|--------------------------|-----------|
| Age (years, mean ± SD) | 62.1 ± 11.9                  | 57.5 ± 12.1              | .146      |
| Body mass index (kg/m², mean ± SD) | 24.0 ± 3.8                  | 26.4 ± 5.4               | .053      |
| Sex (%)                |                              |                          |           |
| - Female               | 19 (57.6%)                   | 14 (53.8%)               | .798      |
| - Male                 | 14 (42.4%)                   | 12 (46.2%)               |           |
| Stoma (%)              |                              |                          |           |
| - Yes                  | 3 (9.1%)                     | 4 (15.4%)                | .688      |
| - No                   | 30 (90.9%)                   | 22 (84.6%)               |           |
| Cancer stage (%)       |                              |                          |           |
| - II                   | 6 (18.2%)                    | 3 (11.5%)                | .858      |
| - III                  | 26 (78.8%)                   | 22 (84.6%)               |           |
| - n.a                  | 1 (3.0%)                     | 1 (3.8%)                 |           |
| Chemotherapy regime (%)|                              |                          |           |
| - FOLFOX               | 16 (48.5%)                   | 17 (65.4%)               | .645      |
| - XELODA               | 8 (24.2%)                    | 4 (15.4%)                |           |
| - XELOX                | 8 (24.2%)                    | 4 (15.4%)                |           |
| - n.a                  | 1 (3.0%)                     | 1 (3.8%)                 |           |

**FOLFOX**, oxaliplatin, fluorouracil, folinic acid; **XELODA**, capecitabine; **XELOX**, oxaliplatin and capecitabine

### Table 2
Effects of a 6-month aerobic exercise intervention on cardiorespiratory fitness, maximal work rate, maximal heart rate, body weight, and body mass index in colorectal cancer patients undergoing adjuvant chemotherapy

|                      | Baseline Mean (SE) | Post-intervention Mean (SE) | Between-group difference from baseline to post-intervention Mean (95% CI) | $P$ value |
|----------------------|--------------------|-----------------------------|-------------------------------------------------------------------------|-----------|
| VO2peak relative (ml/kg/min) |                   |                             |                                                                        |           |
| IG                   | 21.67 (0.55)       | 25.24 (0.63)                | 4.11 (1.52; 6.71)                                                       | .002      |
| CG                   | 21.71 (0.61)       | 21.17 (0.79)                | .587                                                                    |           |
| Wattmax (watt)       |                    |                             |                                                                        |           |
| IG                   | 113.22 (2.17)      | 135.42 (2.50)               | 16.14 (5.71; 26.57)                                                    | .003      |
| CG                   | 113.45 (2.45)      | 119.51 (3.17)               | .136                                                                    |           |
| HRmax (bpm)          |                    |                             |                                                                        |           |
| IG                   | 151.57 (1.67)      | 151.76 (1.92)               | 4.20 (−4.23; 12.63)                                                    | .323      |
| CG                   | 151.65 (1.89)      | 147.64 (2.43)               | .220                                                                    |           |
| Weight (kg)          |                    |                             |                                                                        |           |
| IG                   | 73.95 (0.43)       | 75.62 (0.50)                | −0.70 (−2.77; 1.37)                                                    | .503      |
| CG                   | 73.77 (0.49)       | 76.13 (0.62)                | .004                                                                    | .588      |
| BMI (kg/m²)          |                    |                             |                                                                        |           |
| IG                   | 25.24 (0.14)       | 25.81 (0.16)                | −0.18 (−0.86; 0.49)                                                    |           |
| CG                   | 25.17 (0.16)       | 25.94 (0.21)                | .005                                                                    |           |

**BMI**, body mass index; **CG**, control group; **CI**, confidence interval; **HRmax**, maximal heart rate; **IG**, intervention group; **SE**, standard error; **VO2peak**, peak oxygen uptake; **Wattmax**, maximal work rate

$a$Least square mean and standard error following mixed-model repeated measure analysis

$^bP$ value for changes within groups from baseline to post-intervention
Table 3  Effects of a 6-month aerobic exercise intervention on fatigue in colorectal cancer patients undergoing adjuvant chemotherapy

|                  | Baseline Meana (SE) | 3 months Meana (SE) | Post-intervention Meanb (SE) | Between-group difference from baseline to 3-months Mean difference (95% CI) | Between-group difference from baseline to post-intervention Mean difference (95% CI) |
|------------------|---------------------|---------------------|-----------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|                  |                     |                     |                              | P valueb                                                                 | P valuec                                                                         |
| MFI              |                     |                     |                              | P value                                                                 | P value                                                                         |
| General fatigue  | IG                  | 9.44 (.45)          | 10.63 (.51)                 | .121                                                                      | 10.22 (.54)                                                                    | .751                                                                            | − 1.15                                                                         | .203                                                                            | 1.32                                                                            | .203                                                                            |
|                  | CG                  | 9.66 (.51)          | 12.00 (.60)                 | .003                                                                      | 9.11 (.63)                                                                     | 1.000                                                                          | − 1.83                                                                         | .097                                                                            | − .75                                                                          | .515                                                                            |
| Physical fatigue | IG                  | 10.67 (.49)         | 9.74 (.55)                  | .570                                                                      | 9.71 (.58)                                                                     | .624                                                                            | − 1.83                                                                         | .075                                                                            | − 3.99                                                                         | .333                                                                            |
|                  | CG                  | 10.65 (.55)         | 11.55 (.66)                 | .847                                                                      | 10.45 (.68)                                                                    | 1.000                                                                          | − 3.99                                                                         | .075                                                                            | − 3.03                                                                         | 1.53                                                                            |
| Reduced activity | IG                  | 10.11 (.51)         | 10.37 (.57)                 | 1.000                                                                      | 9.64 (.60)                                                                     | 1.000                                                                          | − .08                                                                          | .940                                                                            | .71                                                                            | .546                                                                            |
|                  | CG                  | 9.92 (.57)          | 10.25 (.68)                 | .003                                                                      | 8.74 (.70)                                                                     | .553                                                                            | − 2.14                                                                         | .015                                                                            | 1.98                                                                            | .040                                                                            |
| Reduced motivation| IG                 | 8.14 (.41)          | 7.87 (.45)                  | 1.000                                                                      | 6.83 (.49)                                                                     | .103                                                                            | − 2.07                                                                         | .015                                                                            | 1.94                                                                            | .091                                                                            |
|                  | CG                  | 7.67 (.46)          | 9.47 (.55)                  | .017                                                                      | 8.30 (.57)                                                                     | .553                                                                            | − 3.73                                                                         | .015                                                                            | − 3.79                                                                         | 0.09                                                                            |
| Mental fatigue   | IG                  | 7.46 (.39)          | 7.22 (.44)                  | 1.000                                                                      | 7.21 (.47)                                                                     | 1.000                                                                          | − 2.23                                                                         | .018                                                                            | − 0.06                                                                         | .950                                                                            |
|                  | CG                  | 7.15 (.44)          | 9.14 (.53)                  | .017                                                                      | 6.96 (.54)                                                                     | 1.000                                                                          | − 1.89                                                                         | .018                                                                            | 1.77                                                                            | .950                                                                            |

*CG, control group; CI, confidence interval; IG, intervention group; MFI, Multidimensional Fatigue Inventory; SE, standard error

a Least square mean and standard error following mixed-model repeated measure analysis

b P value for changes within groups from baseline to 3 months

c P value for changes within groups from baseline to post-intervention
frequency at 3 months (mean difference − 13.21; 95% CI − 24.48−1.93; p = 0.022, Cohen’s d effect size 0.37) as well as blood and mucus in the stool at 3 months and 6 months (mean difference − 12.24; 95% CI − 17.87–6.61, p < 0.001, Cohen’s d effect size 0.52 and mean difference − 10.63; 95% CI − 17.23–4.03; p = 0.002, Cohen’s d effect size 0.42, respectively). Significant time effects were observed for dysuria, abdominal pain, buttock pain, dry mouth, hair loss, trouble with taste, anxiety, and sore skin around anus/stoma.

No significant differences within or between groups were observed for self-reported leisure time and sport activity levels at 3 months or 6 months.

Discussion

A 6-month supervised aerobic exercise program delivered to CRC patients undergoing adjuvant chemotherapy led to significant improvements in CRF and selected patient-reported health outcomes, such as reduced motivation and mental fatigue, compared to usual care. To our knowledge, this is the first study to demonstrate significant improvements in CRF following a supervised aerobic exercise intervention during adjuvant chemotherapy in CRC patients. These results are clinically meaningful given poor CRF has been associated with higher symptom burden and morbidity [10, 11, 25, 32, 33] as well as an increased risk of overall and cancer-specific mortality [12, 13].

Determining the effects of exercise on CRF in CRC patients undergoing adjuvant chemotherapy has been limited by a small number of studies and inconclusive results [18–21]. Our study, however, supports the findings of a recent meta-analysis that included five studies involving CRC patients undergoing chemotherapy in a subgroup analysis and revealed significant effects of exercise on aerobic fitness compared with usual care [17]. Notably, however, none of the studies included in the subgroup analysis assessed a supervised aerobic exercise program, not all patients in the included studies received adjuvant chemotherapy, and only one study assessed VO2peak, the gold standard for assessing CRF. Furthermore, the meta-analytic findings suggest a larger benefit for aerobic fitness for unsupervised interventions in CRC survivors, while we observed a significant effect of supervised exercise [17]. Hence, further randomized controlled trials are warranted to confirm the effects of supervised aerobic exercise on CRF in CRC patients receiving adjuvant chemotherapy.

In our study, CRF improved by 3.57 mL·kg\(^{-1}\)·min\(^{-1}\) (16.5%) in the IG, compared to a decrease of 0.54 mL·kg\(^{-1}\)·min\(^{-1}\) (−2.6%) in the CG. This is an important clinical outcome, given each 1 mL·kg\(^{-1}\)·min\(^{-1}\) increase in CRF has been associated with a −11, 15, and 16% reduction in all-cause, cardiovascular disease, and cancer mortality, respectively, in healthy men and women [34]. While further investigations in CRC patients are required, an increase in physical activity by at least 10 metabolic equivalent task-hour per week (MET-h/week), which corresponds to the exercise prescribed in this study, has been associated with a 28% lower risk of mortality after CRC diagnosis [35]. Our findings and these observations further support the call for prospective studies exploring the effects of exercise and improvements in CRF on key clinical outcomes, such as cancer recurrence and mortality.

The effect of exercise on QoL and fatigue in CRC patients undergoing adjuvant chemotherapy has been inconclusive. While a recent meta-analysis of studies involving CRC patients pre-treatment, during treatment and post-treatment found significant effects of exercise compared to usual care on QoL and fatigue, a subgroup analysis suggested larger effects on QoL post-treatment [17]. In line with the meta-analytic findings and previous studies in CRC patients undergoing chemotherapy, we only observed improvements in selected QoL domains during adjuvant chemotherapy and the effect sizes were mostly small. Yet, the significant improvement in role function that we observed in the IG has also been described by Lin et al., who prescribed a supervised aerobic and resistance exercise program to CRC patients undergoing chemotherapy [18]. While studies in CRC survivors suggest mixed mode exercise interventions or higher doses of aerobic exercise (up to 300 min·wk\(^{-1}\)) may improve health-related QoL more effectively [17, 36], this requires further investigation in CRC patients undergoing chemotherapy. In this study, we focused on aerobic exercise rather than a multimodal intervention, as CRF was our primary outcome and when the study was designed, aerobic exercise showed more beneficial effects on fatigue than other exercise modalities.

Irrespective of the exercise mode or intensity, meta-analyses in cancer patients, including those with CRC and those undergoing chemotherapy, suggest supervised exercise interventions are more effective at improving QoL and fatigue [17, 37, 38]. The significant improvements we observed in reduced motivation and mental fatigue are in line with these findings. Similarly, Van Vulpen et al. found that CRC patients undergoing chemotherapy experience less fatigue when participating in a supervised exercise program involving two supervised sessions per week [20]. Notably, however, they observed improvement in physical and general fatigue, while we observed improvements in reduced motivation and mental fatigue. While meta-analytic data in breast cancer patients undergoing adjuvant treatment suggests that physical fatigue is most sensitive to physical exercise [39], further randomized controlled studies in CRC patients undergoing adjuvant chemotherapy are required to explore what exercise settings, modes and intensities are
most effective at improving the different dimensions of fatigue. Importantly, while effect sizes were small in our study, they are comparable to previous exercise intervention studies during chemotherapy [39] and may still be perceived as clinically relevant. The minimal clinically important difference for changes in fatigue as measured by the MFI has been identified as two points in cancer patients undergoing treatment [40], which corresponds to the differences we observed in general fatigue (within CG), reduced motivation, and mental fatigue.

Apart from fatigue, surgical resection in combination with adjuvant chemotherapy is often associated with other debilitating adverse effects that negatively affect QoL of CRC patients, such as pain, nausea, diarrhea, and mucositis [4–6]. In our study, we observed a significant group effect for urinary frequency as well as blood and mucus in the stool following the supervised aerobic exercise program. Whether this is related to the exercise intervention requires further investigations. Notably, the blood and mucus in the stool scale of the EORTC-QLQ-CR29 has been shown to be only moderately reliable [30, 41], and our results were driven by three patients who reported high scores (> 50) at baseline, two of which were in the CG and withdrew from the study for unrelated issues. Although we observed favorable within-group changes in abdominal pain and dysuria in the IG, while flatulence increased in the CG, preliminary data suggests that more specific exercise modalities, such as pelvic floor muscle training, may be more effective at improving some of the treatment-related side effects of CRC surgery, such as bowel function [42]. Yet, combined aerobic and resistance programs have shown some promise in decreasing pain, nausea, and neurotoxicity symptoms in CRC patients undergoing adjuvant treatment [18, 22]. Given disease- and treatment-related side effects have shown to significantly impact physical activity levels and QoL in CRC patients undergoing adjuvant treatment [8], further investigations focusing on these outcomes would be worthwhile.

While this study underpins that exercise training is feasible and effective in CRC patients undergoing treatment, there are some limitations. The main limitation of the current study is the study design. We chose a non-randomized controlled study design because we anticipated recruitment and compliance challenges based on previous studies conducted with CRC patients. And in fact, compared to the average recruitment rate of 38% (range: 4–91%) in randomized controlled trials involving CRC patients [17], we enrolled 53% of screened patients. While recruitment was slow, the strategy of having clinicians talk to patients about the study and refer them directly may have contributed to this participation rate. The impact of clinician referral on exercise participation has been described previously [43]. The number of patients that did not complete the study (30%) was similar to other studies [20, 25]. Despite the lack of randomization, the two groups were comparable at baseline with regard to patient characteristics and all study outcomes. Nevertheless, given a pragmatic approach was taken to determine the sample size and group allocation was based on patient preference, the findings of this pilot study need to be interpreted with caution and further RCTs are required to confirm the results. This may also be warranted given multiple comparison adjustment was not applied in the present analysis. Furthermore, we did not have access to all medical records to accurately report the actual chemotherapy plan that patients completed (incl. actual duration and dose). A strength of this study is its relatively large sample size and long (supervised) intervention, compared to other studies involving CRC patients undergoing adjuvant chemotherapy. While challenges in engaging CRC patients in exercise trials are commonly reported, we almost managed to reach our target sample size of 60 patients and enroll and assess all patients prior to initiating chemotherapy. Further strengths of our trial that likely contributed to its feasibility were that patients had the option of exercising at their outpatient clinic (e.g., prior to chemotherapy administration) and all training locations were easily accessible (free parking and/or access via public transport). Together with providing supervision, a convenient exercise location has been identified as an important facilitator when it comes to exercise participation and intervention success [14, 43].

Conclusion

Although exercise guidelines recommend CRC patients return to daily activities and physical exercise shortly after surgery and continue to be physical active during nonsurgical treatment [44], studies conducted during adjuvant chemotheraphy for CRC remain scarce. To our knowledge, this is the first study to investigate the effects of a supervised aerobic exercise program in CRC patients undergoing adjuvant chemotherapy. The significant improvements in CRF compared to usual care are promising and clinically meaningful, and hence warrant further randomized controlled trials to confirm these findings and further explore the optimal exercise modes and intensities to improve the health and well-being of CRC patients undergoing adjuvant chemotherapy.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00520-021-06608-9.

Acknowledgements We would like to thank the Praxis Internistischer Onkologie und Hämatologie in Frechen, Praxis Internistischer Onkolgie und Hämatologie in Cologne North, MV-Zentrum für Hämatologie und Onkologie in Cologne, Onkologische Schwerpunktpraxis Richard-Wagner-Straße Cologne, St. Vinzenz-Hospital Cologne, Heilig
References

1. Fitzmaurice C, Abate D, Abbasi N et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.2996

2. Jansen L, Hoffmeister M, Chang-Claude J, Koch M, Brenner H, Arndt V (2011) Age-specific administration of chemotherapy and long-term quality of life in stage II and III colorectal cancer patients: a population-based prospective cohort. Oncologist 16(12):1741–1751. https://doi.org/10.1634/theoncologist.2011-0124

3. Meyers BM, Cosby R, Quareshy F, Jonker D (2017) Adjuvant Chemotherapy for stage II and III colon cancer following complete resection: a cancer care ontario systematic review. Clin Oncol (R Coll Radiol) 29(7):459–465. https://doi.org/10.1016/j.clon.2017.03.001

4. Soveri LM, Lamminmaki A, Hanninen UA, Karhunen M, Bono P, Osterlund P (2019) Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol 58(4):398–406. https://doi.org/10.1080/0284186x.2018.1556804

5. Vardy JL, Dhillon HM, Pond GR, Renton C, Dodd A, Zhang H, Clarke SJ, Tannock IF (2016) Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. Ann Oncol 27(9):1761–1767. https://doi.org/10.1093/annonc/mdw252

6. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzen F, Haller DG (2007) Phase III trial of capcitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25(1):102–109. https://doi.org/10.1200/jco.2006.08.1075

7. Bours MJ, van der Linden BW, Winkels RM, van Duijnhoven FJ, Mols F, van Roekel EH, Kampman E, Beijer S, Weijsenberg MP (2016) Candidate predictors of health-related quality of life of colorectal cancer survivors: a systematic review. Oncologist 21(4):433–452. https://doi.org/10.1634/theoncologist.2015-0258

8. Courneya KS, Friedenreich CM (1997) Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. J Altern Complement Med 3(3):215–226. https://doi.org/10.1089/acm.1997.3.215

9. Cabilan CJ, Hines S (2017) The short-term impact of colorectal cancer treatment on physical activity functional status and quality of life a systematic review. JBI Database System Rev Implement Rep 15(2):517–566. https://doi.org/10.11124/jbisrir-2016003282

10. West MA, Lythgoe D, Barben CP, Noble L, Kemp GJ, Jack S, Grocott MP (2014) Cardiopulmonary exercise variables are associated with postoperative morbidity after major colorectal surgery: a prospective blinded observational study. Br J Anaesth 112(4):665–671. https://doi.org/10.1093/bja/aet408

11. West MA, Asher R, Browning M, Minto G, Swart M, Richardson K, McGarrity L, Jack S, Grocott MP (2016) Validation of preoperative cardiopulmonary exercise testing-derived variables to predict in-hospital morbidity after major colorectal surgery. Br J Surg 103(6):744–752. https://doi.org/10.1002/bjs.10112

12. Schmid D, Leitzmann MF (2015) Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol 26(2):272–278. https://doi.org/10.1093/annonc/mdu250

13. Lakoski SG, Willis BL, Barlow CE, Leonard D, Gao A, Radford NB, Farrell SW, Douglas PS, Berry JD, DeFina LF, Jones LW (2015) Midlife cardiopulmonary fitness, incident cancer, and survival after cancer in men: the Cooper Center Longitudinal Study. JAMA Oncol 1(2):231–237. https://doi.org/10.1001/jamaoncol.2015.0226

14. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH (2019) Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med
15. Cormie P, Zopf EM, Zhang X, Schmitz KH (2017) The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev 39(1):71–92. https://doi.org/10.1093/epirev/mx007

16. van Rooijen SJ, Engelen MA, Scheede-Bergdahl C, Carli F, Roumen RMH, Slootder GD, Schep G (2018) Systematic review of exercise training in colorectal cancer patients during treatment. Scand J Med Sci Sports 28(2):360–370. https://doi.org/10.1111/sms.12907

17. Singh B, Hayes SC, Spence RR, Steele ML, Millet GY, Gergele L (2020) Exercise and colorectal cancer: a systematic review and meta-analysis of exercise safety, feasibility and effectiveness. Int J Behav Nutr Phys Act 17(1):122. https://doi.org/10.1186/s12666-020-01021-7

18. Lin KY, Shun YH, Lai YH, Liang JT, Tsauo JY (2014) Comparison of the effects of a supervised exercise program and usual care in patients with colorectal cancer undergoing chemotherapy. Cancer Nurs 37(2):E21-29. https://doi.org/10.1097/NCC.0b013e3182791097

19. Moller T, Lillelund C, Andersen C, Bloomquist K, Christensen KB, Ejertsson B, Norgaard L, Wiedenbein L, Oturai P, Breitenstein U, Adamsen L (2015) The challenge of preserving cardiopulmonary fitness in physically inactive patients with colon or breast cancer during adjuvant chemotherapy: a randomised feasibility study. BMJ Open Sport Exerc Med 1(1):e000021. https://doi.org/10.1136/bmjsem-2015-000021

20. Van Vulpen JK, Veltius MJ, Steins Bisschop CN, Travier N, Huinink D, Van Der Wall E, Peeters PH, May AM (2016) Effects of an exercise program in colon cancer patients undergoing chemotherapy. Med Sci Sports Exerc 48(5):767–775. https://doi.org/10.1249/01.MSS.0000000000000855

21. van Waar H, Stuiver MM, van Harten WH, Geleijnse J, de Maaker-Berkhof M, Schrama J, Geenen MM, Meerum Terwogt GB, 12907 Anwendung Sozial- und Präventivmedizin 44(2):55–64. https://doi.org/10.1016/S0039-6109(02)00078-3

22. Van Vulpen JK, Veltius MJ, Steins Bisschop CN, Travier N, Huinink D, Van Der Wall E, Peeters PH, May AM (2016) Effects of an exercise program in colon cancer patients undergoing chemotherapy. Med Sci Sports Exerc 48(5):767–775. https://doi.org/10.1249/01.MSS.0000000000000855

23. Fairman CM, Focht BC, Lucas AR, Lustberg MB (2016) Effects of exercise interventions during different treatments in breast cancer. J Community Support Oncol 14(5):200–209. https://doi.org/10.12788/jcsco.0225

24. Maginador G, Lixandrão ME, Bortolozo HI, Vechin FC, Sarian MS (2020) Aerobic exercise-induced changes in cardiopulmonary fitness in breast cancer patients receiving chemotherapy: a systematic review and meta-analysis. Cancers (Basel) 12(8):2240. https://doi.org/10.3390/cancers12082240

25. Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Fairey AS (2003) A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care (Engl) 12(4):347–357. https://doi.org/10.1046/j.1365-2354.2003.00437.x

26. G B (1998) Borg’s perceived exertion and pain scales.

27. Scott JM, Hornsby WE, Lane A, Kenjale AA, Eves ND, Jones LW (2015) Reliability of maximal cardiopulmonary exercise testing in men with prostate cancer. Med Sci Sports Exerc 47(1):27–32. https://doi.org/10.1249/MSS.0000000000000370

28. Smit EM, Garssen B, Boekoe B, De Haes JC (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39(3):315–325. https://doi.org/10.1016/0022-3999(94)00125-o

29. Aaronson NK, Ahmedzai S, Bergman B, Fayers PM, Karnold M, Linnell C, Bjorn-Efse P, Puliyblank AM, Fayers P, Blazey JM (2009) Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer 45(17):3017–3026. https://doi.org/10.1016/j.ejca.2009.08.014

30. Frey I, Berg A, Grathwohl D, Keul J (1999) Freiwillige Fragebogen zur körperlichen Aktivität-Entwicklung. Prüfung und Anwendung Sozial-und Präventivmedizin 44(2):55–64. https://doi.org/10.1002/hsb.9551

31. West MA, Loughney L, Barben CP, Sripadam R, Kemp GJ, Grocott MP, Jackson S (2014) The effects of non-adjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients. Eur J Surg Oncol 40(11):1421–1428. https://doi.org/10.1016/j.ejso.2014.03.021

32. West MA, Parry MG, Lythgoe D, Barben CP, Kemp GJ, Grocott MP, Jackson S (2014) Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal cancer surgery. Br J Surg 101(9):1166–1172. https://doi.org/10.1002/bjs.9551

33. Imboden MT, Harber MP, Whaley MH, Finch WH, Bishop DL, Fleenor BS, Kaminsky LA (2019) The association between the change in directly measured cardiorespiratory fitness across time and mortality risk. Prog Cardiovasc Dis 62(2):157–162. https://doi.org/10.1016/j.pcad.2018.12.003

34. Schmid D, Leitzmann MF (2014) Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol 25(7):1293–1311. https://doi.org/10.1093/annonc/mdu012

35. Brown JC, Damjanov N, Courneya KS, Troxel AB, Zemel BS, Rickels MR, Ky B, Rhim AD, Rustgi AK, Schmitz KH (2018) A randomized dose-response trial of aerobic exercise and health-related quality of life in colon cancer survivors. Psychooncology 27(4):1221–1228. https://doi.org/10.1002/pon.4655

36. Meneses-Echavez JF, Gonzalez-Jimenez E, Ramirez-Velez R (2015) Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer 15:77. https://doi.org/10.1186/s12885-015-1069-4

37. Buffart LM, Calter J, Sweeney MG et al (2017) Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev 52:91–104. https://doi.org/10.1016/j.ctrv.2016.11.010

38. van Vulpen JK, Peeters PH, Veltius MJ, van der Wall E, May AM (2016) Effects of physical exercise during adjuvant breast cancer treatment on physical and psychosocial dimensions of cancer-related fatigue: a meta-analysis. Maturitas 85:104–111. https://doi.org/10.1016/j.maturitas.2015.12.007

39. Purcell A, Fleming J, Bennett S, Burmeister B, Haines T (2010) Determining the minimal clinically important difference criteria for the Multidimensional Fatigue Inventory in a radiotherapy
41. Stiggelbout AM, Kunneman M, Baas-Thijssen MC, Neijenhuis PA, Looij AK, Jagers S, Vree R, Marijnen CA, Pieterse AH (2016) The EORTC QLQ-CR29 quality of life questionnaire for colorectal cancer: validation of the Dutch version. Qual Life Res 25(7):1853–1858. https://doi.org/10.1007/s11136-015-1210-5

42. Lin KY, Granger CL, Denehy L, Frawley HC (2015) Pelvic floor muscle training for bowel dysfunction following colorectal cancer surgery: a systematic review. Neurourol Urodyn 34(8):703–712. https://doi.org/10.1002/nau.22654

43. Livingston PM, Craike MJ, Salmon J, Courneya KS, Gaskin CJ, Fraser SF, Mohebbi M, Broadbent S, Botti M, Kent B (2015) Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: a multicenter cluster randomized controlled trial (ENGAGE). Cancer 121(15):2646–2654. https://doi.org/10.1002/cncr.29385

44. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42(7):1409–1426. https://doi.org/10.1249/MSS.0b013e3181e0c112

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.